Clinical Trial Update: Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating allogeneic hematopoietic stem cell transplantation for systemic sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Snippet

Sponsor: Richard Burt, MD | Conditions: Scleroderma | Phase 1 | Status: TERMINATED